Madrigal Pharmaceuticals (MDGL) Competitors

Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Which has more volatility & risk, BIIB or MDGL?

Biogen has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.02, meaning that its share price is 202% less volatile than the S&P 500.

Do analysts prefer BIIB or MDGL?

Biogen currently has a consensus price target of $185.74, suggesting a potential upside of 35.44%. Madrigal Pharmaceuticals has a consensus price target of $439.71, suggesting a potential upside of 16.80%. Given Biogen's higher possible upside, equities analysts plainly believe Biogen is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	21 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.34
Madrigal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Do insiders and institutionals have more ownership in BIIB or MDGL?

87.9% of Biogen shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media prefer BIIB or MDGL?

In the previous week, Biogen had 4 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 38 mentions for Biogen and 34 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 1.06 beat Madrigal Pharmaceuticals' score of 0.70 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	23 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	19 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings and valuation, BIIB or MDGL?

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	2.08	$1.63B	$10.46	13.11
Madrigal Pharmaceuticals	$180.13M	46.40	-$465.89M	-$12.85	-29.30

Is BIIB or MDGL more profitable?

Biogen has a net margin of 15.31% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Biogen's return on equity of 13.85% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	15.31%	13.85%	8.32%
Madrigal Pharmaceuticals	-54.68%	-38.38%	-27.32%

Summary

Biogen beats Madrigal Pharmaceuticals on 12 of the 16 factors compared between the two stocks.